Kirby McInerney LLP is investigating potential claims against the Board of Directors of ViroPharma Incorporated (“ViroPharma” or the “Company”) (NASDAQ:VPHM) concerning the proposed acquisition of the Company by Shire plc (“Shire”). Under the terms of the proposed transaction, ViroPharma stockholders will receive $50.00 in cash for each share of ViroPharma owned, valuing the transaction at approximately $4.2 billion. The investigation concerns whether the ViroPharma Board of Directors violated its fiduciary duties by agreeing to the proposed transaction and whether the $50.00 per share proposed consideration adequately values ViroPharma’s common stock. If you are a ViroPharma stockholder and wish to obtain additional information, please contact J. Brandon Walker, Esq. by email at firstname.lastname@example.org, by telephone at (212) 699-1145 or (888) 529-4787, or by filling out this contact form. There is no cost or obligation to you. Kirby McInerney LLP is a New York-based law firm concentrating in securities, stockholder, whistleblower, antitrust and consumer litigation. For additional information, please go to www.kmllp.com.
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.